![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, May 05, 2011 5:13:47 PM
As an unapproved solution, over 4 million prescriptions are written annually in the States for therapies to treat hemorrhoids alone with more than 22 million over the counter units sold. Ventrus estimates to sell their hemorrhoid therapy for $350 per unit. Without ever making the grand assumptions that 100 percent of market share would be captured, the scenario represents a value of $7.7 billion based on current figures. That goes without mentioning the potential revenue that can be derived from fecal incontinence and anal fissure patients which could push the total considerably higher.
With a total debt of less than $3 million, three drugs in late-stage clinical development and only 9.3 million fully-diluted shares, Ventrus is already starting to capture the attention of the investment community. While it may be true for a biotechnology company that “He conquers who endures,” in the world of biotech investing the phrase “the early bird catches the worm” may be more appropriate.
FEATURED Element79 Gold Corp Appoints Warren Levy to Board of Directors • Aug 28, 2024 9:51 AM
Integrated Ventures Announces Strategic Entry Into Health & Wellness Industry with Focus on GLP-1 Products • INTV • Aug 28, 2024 8:30 AM
ELEMENT79 ANNOUNCES UPLISTING TO OTCQB VENTURE MARKET • ELMGF • Aug 26, 2024 10:03 AM
North Bay Resources Announces Gold Assays up to 2.2 Ounces per Ton, Fran Gold Project, British Columbia • NBRI • Aug 26, 2024 10:00 AM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM